Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fecal Hemoglobin Concentrations Varies with Gender and Age

By LabMedica International staff writers
Posted on 05 Jul 2012
Estimation of fecal hemoglobin concentration by fecal immunochemical tests (FIT) are becoming widely used in colorectal cancer screening.

Risk stratification is based on the concentration of the hemoglobin in the stool specimens and this helps clinicians make the subsequent decisions for diagnosis and treatment of colorectal neoplasia. More...


Scientists at the University of Dundee (UK) carried out a large observational study by making a single estimate of fecal hemoglobin concentration using quantitative automated immunoturbidimetry. From July 1, 2010, to January 12, 2011, all eligible men and women aged between 50 and 74 years resident in two of the 14 National Health Service Boards in Scotland were invited to participate. To investigate potential reference values, those who returned a testable fecal sample were defined as the reference population. No exclusion criteria were applied.

The reference sample group comprised of 38,720 in total, including 18,058 men (46.6 %) and 20,662 women (53.4 %) who returned a testable sample. The potential upper reference limits, were 519 ng hemoglobin/mL (90% Confidence Interval (CI): 468-575) for men and 283 ng hemoglobin/mL (90% CI: 257-316) for women. The concentration of hemoglobin increased with age in both genders. The decision limits have advantages over the reference intervals. At any cut-off concentration, more men are declared positive than women and more older people are declared positive than younger people. Future risk of neoplasia is higher in men than in women and in older people.

The authors concluded that that the truly healthy individual has no detectable fecal hemoglobin by conventional quantitative methodology and that any hemoglobin present is unusual. Fecal hemoglobin concentrations vary with gender and age and should be included in individual risk assessment scores. They suggest that more tailored strategies are needed in colorectal cancer screening programs. The study was published on May 25, 2012, in the journal Clinical Chemistry and Laboratory Medicine.

Related Links:

University of Dundee



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.